文献速递细胞病理与分子病理胸部病理

PD-L1/TTF-1双免疫组化染色助力肺腺癌细胞学标本PD-L1评分

Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.
PubMed 文献 · Cancer Cytopathol · 2020-09-25

该研究在42对肺腺癌细胞学与组织学标本中比较PD-L1单染与PD-L1/TTF-1双染。双染在细胞学标本中能更好识别PD-L1阳性肿瘤细胞,使病理医师视觉估读与技师计数分类的一致性(加权kappa)从0.784升至0.880,并将视觉估读可能误差从9.5%降至4.8%,组织学标本未见此获益。

要点

  • PD-L1/TTF-1双染可提升细胞学标本肿瘤PD-L1阳性细胞识别。
  • 双染使细胞学标本视觉估读与200细胞计数的分类一致性提高。
  • 双染将细胞学标本病理医师视觉估读可能误差从9.5%降至4.8%。

核心结论

  • PD-L1/TTF-1双免疫组化技术可成功用于细胞学标本,更好识别可能从免疫检查点阻断治疗获益的患者。

研究设计与样本

  • 在42对肺腺癌患者的细胞学与组织学标本中行PD-L1单染和PD-L1/TTF-1双染。
  • 由经验丰富的病理医师视觉估读PD-L1表达并分为<1%、1%-49%、≥50%三类。
  • 由医学技师基于200个肿瘤细胞计数对同批病例进行估读并比较。

主要发现

  • 与PD-L1单染相比,PD-L1/TTF-1双染在细胞学标本中能更好识别PD-L1阳性肿瘤细胞。
  • 细胞学标本中病理医师视觉估读与技师计数的分类一致性(加权kappa)单染为0.784,双染为0.880。
  • 双染将病理医师视觉估读PD-L1表达的可能误差从9.5%降至4.8%。
  • 上述获益未在组织学标本中观察到。

关键数值与推荐

  • PD-L1表达分类阈值:<1%、1%-49%、≥50%。
  • 一致性评价指标:Cohen加权kappa,单染0.784,双染0.880。
  • 视觉估读可能误差:单染9.5%,双染4.8%。
  • 技师计数基于200个肿瘤细胞。

临床怎么用

  • 在肺腺癌细胞学标本PD-L1评分中可采用PD-L1/TTF-1双染辅助识别肿瘤细胞。
  • 双染有助于提高病理医师视觉估读与细胞计数分类的一致性。

局限性

  • 组织学标本中未观察到双染带来的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitor therapy has revolutionized lung adenocarcinoma therapy. Treatment with antibodies against the immune checkpoint molecules programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) can induce a durable response in a subset of patients. Immunohistochemistry characterization of tumor PD-L1 expression using either a histopathology specimen or a cytopathology specimen has been shown to correlate with treatment response. However, the current practice relies on pathologists' visual estimation of tumor PD-L1 staining, which can be variable in certain conditions. Highlighting tumor cells via double immunostaining with PD-L1 and thyroid transcription factor-1 (TTF-1) may improve estimation accuracy. METHODS: We performed PD-L1 single staining and PD-L1/TTF-1 double staining in 42 pairs of cytopathology and histopathology specimens from lung adenocarcinoma patients. An experienced pathologist visually estimated PD-L1 expression in each case and placed tumor PD-L1 expression into 1 of 3 categories: <1%, 1%-49%, or ≥50%. A medical technologist also performed estimations of the same cases based on a count of 200 tumor cells, and the results were compared. RESULTS: PD-L1/TTF-1 double immunohistochemistry could better identify the PD-L1-positive tumor cells in cytopathology specimens compared with PD-L1 single staining. The concordance of PD-L1 expression categorization between the pathologist's visual estimation and the medical technologist's counting was increased by double staining in cytopathology specimens (Cohen's weighted kappa: single stain, 0.784; double stain, 0.880). Double staining reduced possible error in the pathologist's visual estimation of PD-L1 expression from 9.5% to 4.8%. The benefit was not observed in histopathology specimens. CONCLUSION: A simple PD-L1/TTF-1 double immunohistochemistry technique can be applied successfully to cytopathology specimens in better identifying patients who can potentially benefit from immune checkpoint blockade treatment.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Lin YY, Lin LY, Hang JF, et al. Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients. Cancer Cytopathol. 2020. PMID: 32976705. doi:10.1002/cncy.22359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。